Matt Britz

Biotech CEO, working on a great cancer drug! Check out Saros Tx! (Opinions are my own)

[Aaron Ring @aaronmring]

How specific are therapeutic monoclonal antibodies, really?

In our new paper, @Yile_Dai led a collaboration with Adimab to profile 174 FDA-approved and clinical-stage mAbs against 6,172 human extracellular proteins.

What we found surprised us.🧵

https://t.co/ONTSF60B2g

[AffyImmune Therapeutics @affyimmune]

Excited to share our upcoming poster presentation at #ASCO24 @ASCO
where we will present a confirmed complete response in a patient with Anaplastic #Thyroid Cancer with our autologous CAR T therapy AIC100.

https://t.co/U0hd8jNaCg

[Matt Britz @mattbritz]

Proud to announce that Affy has achieved a complete response in an anaplastic thyroid cancer patient in our Phase 1 trial with AIC100, our autologous CAR T cell product #ASCO24
https://t.co/eK8fMHVcnK

[Jeremy Reiner @jreineron7]

From Phillips Beach in Swampscott! 📸 Jackie D

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

Happy CD3/CD28 T Cell Activation Day! 3/28

[Matt Britz @mattbritz]

I have news…. Also, so happy to have Pete join the Affy team!

[Latest News from Business Wire @NewsFromBW]

AffyImmune Therapeutics Appoints Matt Britz as Chief Executive Officer and Pete Gelinas as SVP of CMC https://t.co/bwjMnoJFiO

[Scrip, Citeline Commercial @PharmaScrip]

The Best Oncology R&D Advance Award has been handed to AffyImmune Therapeutics’ (@affyimmune) AIC100 ICAM-1 targeting CAR T cell therapy. Well done on your win!

https://t.co/m6Q7SRxDdp

#ScripAwards #ScripAwards2023 #Citeline

[Scrip, Citeline Commercial @PharmaScrip]

Eisai And Eli Lilly Triumph At The 19th Annual Scrip Awards
https://t.co/RZ9nAW9RjY #PharmaScrip

[AffyImmune Therapeutics @affyimmune]

We are thrilled to announce that AffyImmune Therapeutics was selected as the winner of the Best Oncology R&D Advance Award last night at the 2023 Scrip Awards! Congratulations to our full team and thank you all for your hard work and dedication to our mission. #Oncology #CARTcell

[AffyImmune Therapeutics @affyimmune]

Join Chief Operating Officer @mattbritz today at 5:00 pm PT in the Rentschler ATMP Ballroom for his presentation at @alliancerm’s #CGMesa23! The presentation will be available to virtual attendees on the event livestream – see below link to register:
https://t.co/jRPveWymlh

[AffyImmune Therapeutics @affyimmune]

AffyImmune Therapeutics is excited to share that it’s recently named as one of the Best Oncology R&D Advances as a 2023 finalist for the @Citeline Scrip Awards! The winner will be announced in London on November 16, 2023.

https://t.co/EpgpU2Yn2L

#oncology #CARTcell

[AffyImmune Therapeutics @affyimmune]

Live from New York, it's... AffyImmune!

Our friends at @tryramp gave us a boost in Times Square, featuring a tweet by @Cornell_CTL about our clinical data from #ASCO23

Thanks to Ramp for the surprise and to our partners helping deliver AIC100 to patients in our clinical trial!

[Matt Britz @mattbritz]

@bradloncar

[Angelos Georgakis @angelosgeo]

Jan Skvarka took Trillium Therapeutics from a $16 million market capitalisation to a $2.26 billion acquisition by Pfizer in only 2 years and in the midst of the pandemic.

The story and 6 lessons on biotech strategy, culture, and success. 🧵

[AffyImmune Therapeutics @affyimmune]

We are encouraged by positive safety & early efficacy results from our Phase 1 study of AIC100 CAR T cells in anaplastic & advanced thyroid cancers to be presented at #ASCO23, with an unprecedented partial response for a patient with ATC! #CARtcelltherapy #thyroidcancer #biotech

[Brad Loncar @bradloncar]

#ASCO23 5:00PM ET today: Majority of abstracts released on https://t.co/CI6HvncDCR (Late-breaking Abstracts will be released on a rolling basis during the meeting)

[Shayna @shaynagoldman_]

PASTA

[Matt Britz @mattbritz]

Kite acquired Tmunity - deal closed last week. Did you know they paid approx $300 million for the shares they didn't already own? #cartcells

[Teiko @TeikoLabsHQ]

Exciting #IO360nyc keynote by Dr. @MarcelaMaus of MGH on #solidtumors & #CART. Loss of IFNyR signaling in solid tumors can drive resistance and CAR-T cytotoxicity suggesting a “crucial role of IFNyR in stabilizing and enhancing solid tumor CAR T cell interactions.”#CancerResearch

[Amit Agarwal @agarwalonc]

Dose–response correlation for CAR-T cells: a systematic review of clinical studies https://t.co/CouvsLR8En